Notice: This company has been marked as potentially delisted and may not be actively trading. OTCMKTS:AGYTF Allergy Therapeutics (AGYTF) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisHeadlinesShort Interest About Allergy Therapeutics Stock (OTCMKTS:AGYTF) 30 days 90 days 365 days Advanced Chart Remove Ads Get Allergy Therapeutics alerts:Sign Up Key Stats Today's Range$0.05▼$0.0550-Day Range N/A52-Week Range$0.17▼$0.19VolumeN/AAverage VolumeN/AMarket Capitalization$35.83 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAllergy Therapeutics plc engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, Acarovac MPL, Venomil, Synbiotics, Penicillin Diagnostics, and Peanut. The company also develops allergy vaccines for grass, tree, and house dust mite, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.Read More… Remove Ads Receive AGYTF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Allergy Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AGYTF Stock News HeadlinesAllergy Therapeutics grants options to key managementFebruary 14, 2025 | msn.comAllergy Therapeutics Shows Promising Results for Peanut AllergyDecember 5, 2024 | markets.businessinsider.comBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chipmaker has struggled this year, facing increased competition and regulatory pressure.March 12, 2025 | Chaikin Analytics (Ad)Allergy Therapeutics Begins Innovative Paediatric Allergy TrialNovember 27, 2024 | markets.businessinsider.com3 Best Drawing Exercises to Improve Your Art (DYNAMIC LINES INSTANTLY- AT ANY LEVEL!)November 1, 2024 | msn.comWhy are food allergies on the rise?October 31, 2024 | bbc.co.ukSNEAKING INTO MY POOL AT 3AM ON A SCHOOL NIGHT **Again**October 30, 2024 | msn.comBEACH CLUB AT THE BOCA RATON COLLABORATES WITH ACCLAIMED CHEF JOHNNY SPERO FOR THE OPENING OF MARISOL RESTAURANTOctober 29, 2024 | finance.yahoo.comSee More Headlines Company Calendar Today3/12/2025Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Private households Sub-IndustryN/A Current SymbolOTCMKTS:AGYTF Previous SymbolNASDAQ:AGYTF CIKN/A Webwww.allergytherapeutics.com Phone44-19-0384-4700FaxN/AEmployees600Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio7.78 Current Ratio1.63 Quick Ratio1.01 Sales & Book Value Annual Sales$69.51 million Price / Sales0.52 Cash FlowN/A Price / Cash FlowN/A Book Value$0.01 per share Price / Book5.20Miscellaneous Outstanding Shares688,950,000Free FloatN/AMarket Cap$35.83 million OptionableNot Optionable Beta525.43 These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (OTCMKTS:AGYTF) was last updated on 3/12/2025 by MarketBeat.com Staff From Our PartnersDeFi Coin on Verge of Breakout!We’re Opening the Ultimate Crypto Vault… Don't let this be the missed opportunity you regret for years. Crypto 101 Media | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredDOGE’s Next Move: Not what you thinkDonald Trump, Elon Musk and the Department of Government Efficiency have kept their word. Moving even faste...Weiss Ratings | SponsoredYour Wealth is Under AttackHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allergy Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Allergy Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
